INTRODUCTION

Ilaprazole (ILA), chemically is known as 2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole, (trade name
) is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. Domperidone (DOM), chemically is known as 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one, a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. This combination of drugs will be used to treat peptic ulcers. [1] [2] The literature is enriched with several methods for determination of ILA and DOM in pharmaceutical dosage forms either as a single drug or in combination with some other drugs. The most extensively used technique for estimation of ILA are by UV 3 HPLC 4 , UPLC 5 and LC-MS/MS 6 methods and most extensively used technique for estimation of DOM are by UV [7] [8] [9] and RP-HPLC [10] [11] [12] [13] [14] [15] [16] [17] . The aim of study is Development and Validation of Analytical HPLC method for Simultaneous Estimation of Ilaprazole and Domperidone in their combined Dosage form.
The present study was designed to develop a simple, precise, and rapid analytical RP-HPLC procedure, which can be used for the analysis of assay method for simultaneous estimation of Ilaprazole and Domperidone as there was only individual methods reported for both drugs. The combination of these two drugs is not official in any pharmacopoeia; hence no official method is available for the simultaneous estimation of these two drugs in their combined dosage forms. Literature survey of Ilaprazole and Domperidone revealed several methods for detecting these drugs individually but there is no method for their simultaneous estimation using RP-HPLC. 
MATERIAL AND METHODS
Apparatus and Instrument
The analysis was carried out on a HPLC system (Shimadzu LC-20-AT) equipped with UV detector. Other apparatus and instruments used were a micro analytical balance (Shimadzu), Ultrasonic Cleaner (EIE Instruments Pvt. Ltd. Ahmedabad), Nylon Membrane Filters (0.22mcm, 47 mm D). All instruments and glass wares were calibrated.
Reagents and Materials
Ilaprazole and Domperidone were obtained as gratis sample from Accurate Pharmaceuticals, Godhra. Methanol HPLC Grade, Water HPLC Grade, Phosphate Buffer, O-Phosphoric Acid was used which were obtained from Samir Tech-Chem Pvt. Ltd. A stockstandard solution of ILA and DOM was prepared by dissolving accurately weighed amount of pure drug in mobie phase.
Mobile Phase:
Phosphate Buffer (pH 3): Methanol(40:60 v/v). The mobile phase was filtered through Millipore filter paper type HV (0.45 µm) and degassed by sonication.
Chromatographic conditions
Chromatographic analysis was carried out on an inertsil C-18 column, (5 µm, 250mm x 4.6mm i.d) LC-20 AT. The mobile phase consisted of Phosphate Buffer (pH 3): Methanol (40:60 v/v). The mobile phase was filtered through Millipore filter paper type HV (0.45 µm) and degassed by sonication, was pumped at 1.0 ml/min flow rate. The column was thermostated at room temperature. Under these conditions the runtime was 10 min.
Preparation of standard stock solution of
Ilaprazole (100 μg/ml) and Domperidone (300μg/ml) A 10 mg of standard Ilaprazole and 30 mg of standard Domperidone was weighed and transferred to a 100 ml volumetric flask each and dissolved in 25 ml mobile phase. The flask was shaken and volume was made up to the mark with mobile phase to give a solution containing 100 μg/ml Ilaprazole and 300 μg/ml Domperidone.
Preparation of combined working standard solution containing Ilaprazole and Domperidonein ratio of 1:3
Accurately weighed 10 mg Ilaprazole and 30 mg of Domperidone were transferred to 100 ml volumetric flask, dissolved in sufficient amount of mobile phase and diluted up to mark with mobile phase to get concentration of 100 μg/ml Ilaprazole and 300 μg/ml Domperidone. This solution was diluted further to get the concentrations in range of 5, 7.5, 10, 12.5, 15 μg/ml of Ilaprazole and 15, 22.5, 30, 37.5, 45 μg/ml of Domperidone.
Method Validation
Precision
Repeatability: Precision of the method was studied by making repeated injections of the mixture of drugs on the same day for intraday precision. The % RSD after six determinations was determined at 10 µg/ml for ILA and 30 µg/ml for DOM.
Intraday and Inter-day Precision:
Intraday and Interday precision for method were measured in term of %RSD. The experiment was repeated three times in a day for intraday and on three different days of same for inter-day precision by taking lower, middle and higher concentration of ILA(5, 10, 15 µg/ml) and DOM(15, 30, 45 µg/ml).
Linearity:
The linearity of measurement was evaluated by analyzing standard solutions of ILA and DOM in the range of 5-15 µg/ml and 15-45 µg/ml for both drugs respectively and calibration plot was constructed.
Limit of Detection (LOD) and Limit of Quantitation (LOQ):
LOD and LOQ of ILA and DOM were determined by calibration curve method. Solutions of Ilaprazole and Domperidone were prepared in the range of 5-15 µg/ml and 15-45 µg/ml for both drugs respectively and injected in triplicate.
Accuracy:
Accuracy of the method was calculated by recovery studies at three levels by standard addition method i.e. spiking 80%, 100%, 120% of ILA and DOM to the standard solutions containing 5 µg/ml of ILA and 15 µg/ml of DOM.
Robustness:
Influence of small changes in chromatographic conditions such as change in flow rate, that is, ± 0.2 ml/min, mobile phase composition ±2 ml and pH ± 0.2 was studied to determine the robustness of the method for the development of RP-HPLC method for the simultaneous estimation of ILA and DOM and their %RSD was determined.
System Suitability:
The stock solution containing 10 µg/ml of ILA and 30 µg/ml of DOM was injected and repeated five times and the chromatograms were recorded. The resolution, number of theoretical plates, and peak asymmetry were calculated to determine whether the result complies with the recommended limit. The wavelength selected was the Isobestic point from the overlay of Ilaprazole and Domperidone. Both the drugs showed typical peak nature and peaks were symmetrical at 229 nm which is the Isobestic point. Hence the wavelength has been selected as the detection wavelength.
RESULTS AND DISCUSSION
Validation
Linearity and Range
The linearity of measurement was evaluated by analyzing standard solutions of ILA and DOM in the range of 5-15 µg/ml and 15-45 µg/ml respectively for both drugs and calibration plot was constructed. 
Precision
Precision of the method was studied by making repeated injections of the mixture of drugs. The Relative Standard Deviation (%RSD) after six determinations was 0.7% at 10 μg/ml for ILA and 0.81% at 30 μg/ml for DOM (see Table 2 ). 
LOD and LOQ
LOD and LOQ of ILA and DOM were determined by calibration curve method. Solutions of ILA and DOM were prepared in the range of 5-15 μg/ml and 15-45 μg/ml respectively and injected in triplicate (see Table  1 ).
Accuracy
Accuracy of the method was calculated by recovery studies at three levels by standard addition method. The mean percentage recoveries obtained for ILA and DOM were 99.61% and 99.64%, respectively (see Table 3 ). 
Robustness
The method for the development of RP-HPLC method for the simultaneous estimation of ILA and DOM was found to be robust as the % RSD was found to be less than 2 (see Table 4 ) 
System Suitability
The resolution, number of theoretical plates, and peak asymmetry were calculated for the standard solutions. The stock solution containing 10 μg/ml of ILA and 30 μg/ml of DOM was injected and repeated five times and the chromatograms were recorded. The resolution, number of theoretical plates, and peak asymmetry were calculated to determine whether the result complies with the recommended limit (see Table 5 )
. Manufacturer: Lupin Pharma, Mumbai, Maharashtra, India.
Preperation of sample solution:
LUPILA-D capsule containing 10 mg of ILA and 30 mg of DOM is available in local market which is marketed by Lupin Pharma(Mumbai). For estimation of Ilaprazole and Domperidone mixture was prepared. Mixture equivalent to 10 mg of Ilaprazole and 30 mg of Domperidone was accurately weighed and transferred to volumetric flask of 1000ml capacity. 25 ml of mobile phase was transferred to volumetric flask and Sonicate for 15 mins. The flask was shaken and volume was made up to the mark with mobile phase. The above solution was filtered through Whatman filter paper (0.75μ). From this solution 10 ml was transferred to volumetric flask of 100 ml capacity. Volume was made up to the mark using mobile phase to give a solution containing 100 μg/ml Ilaprazole and 300 μg/ml Domperidone (solution A).
From the solution A, 1 ml was transferred to volumetric flask of 10 ml capacity and volume was made up to the mark using mobile phase to give a solution containing 10 μg/ml Ilaprazole and 30 μg/ml Domperidone. This solution was used for the estimation of Ilaprazole and Domperidone. 
CONCLUSION
The proposed RP-HPLC method was used for the simultaneous estimation of Ilaprazole and Domperidone was found to be sensitive, accurate, precise, simple, and rapid. Hence the present RP-HPLC method may be used for routine analysis of the raw materials as well as combined dosage formulations containing Ilaprazole and Domperidone.
